NAD+ vs NMN vs NR: Comparing NAD Precursors for Longevity Research

**Disclaimer:** This article is provided for educational and research purposes only. [NAD+](/catalog/nad-plus) precursors are sold as dietary supplements and are not FDA-approved for the treatment or prevention of any disease. Nothing in this article constitutes medical advice.

Introduction

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, essential for hundreds of enzymatic reactions including mitochondrial energy production, DNA repair, and sirtuin-mediated gene regulation. NAD+ levels decline with age --- a phenomenon increasingly recognized as a driver of age-related metabolic dysfunction. This decline has made NAD+ repletion a central focus of longevity research, with two primary precursor molecules competing for attention: nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR).

This comparison examines the biosynthetic pathways, cellular transport mechanisms, bioavailability data, key clinical trial results, and the ongoing scientific debate about which precursor most effectively restores intracellular NAD+ levels.

NAD+ Biosynthesis Pathways

NAD+ can be synthesized through three primary routes in mammalian cells: the de novo pathway from tryptophan, the Preiss-Handler pathway from nicotinic acid, and the salvage pathway from nicotinamide (NAM). The salvage pathway handles the vast majority of NAD+ turnover in adult tissues and is the pathway most relevant to NMN and NR supplementation.

In the salvage pathway, nicotinamide is first converted to NMN by the rate-limiting enzyme nicotinamide phosphoribosyltransferase (NAMPT). NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs), of which there are three isoforms localized to the nucleus (NMNAT1), cytoplasm/Golgi (NMNAT2), and mitochondria (NMNAT3).

NR enters the pathway differently. It is first phosphorylated to NMN by nicotinamide riboside kinases (NRK1 and NRK2), discovered by Bieganowski and Brenner in 2004. This means NR converges on the same pathway as NMN one step earlier, requiring NRK-mediated phosphorylation before it can be converted to NAD+ by NMNATs.

The Cell Membrane Transport Question

A fundamental scientific debate has centered on whether NMN can cross cell membranes directly or must first be dephosphorylated to NR for uptake. This question has major implications for understanding how oral NMN supplementation raises intracellular NAD+.

In 2019, Grozio et al. identified a dedicated NMN transporter, Slc12a8, expressed in the small intestine, liver, and other tissues. This transmembrane protein was shown to transport intact NMN into cells in a sodium-dependent manner. Knockout of Slc12a8 in mice reduced NMN uptake and attenuated the NAD+-boosting effects of oral NMN administration. This was a significant finding because it provided a molecular mechanism for direct NMN uptake without prior conversion to NR.

However, this finding did not settle the debate entirely. Some researchers have argued that the contribution of Slc12a8-mediated direct transport relative to CD73/ecto-5'-nucleotidase-mediated dephosphorylation to NR remains unclear in quantitative terms. The ectoenzyme CD73, located on the extracellular surface of many cell types, can cleave the phosphate group from NMN to generate NR, which then enters cells via equilibrative nucleoside transporters (ENTs). It is likely that both pathways operate in parallel, with their relative contributions varying by tissue type and metabolic state.

NR enters cells through equilibrative nucleoside transporters (ENTs), which are widely expressed across tissues. This well-characterized transport mechanism is one argument in favor of NR's bioavailability --- the transport machinery for nucleoside uptake is ubiquitous and well understood.

Direct supplementation with NAD+ itself faces significant barriers. NAD+ is a large, charged molecule (molecular weight 663 Da with a pyrophosphate group) that does not readily cross cell membranes. While intravenous NAD+ administration has been explored, oral NAD+ is thought to be largely degraded in the GI tract before reaching target tissues.

Clinical Trial Evidence

NMN: Yoshino et al. (2021)

The landmark human clinical trial for NMN was published by Yoshino et al. in Science in 2021. This randomized, placebo-controlled, double-blind trial enrolled 25 postmenopausal women with prediabetes and overweight/obesity. Participants received 250 mg/day NMN or placebo for 10 weeks. The primary findings were a significant increase in skeletal muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) and increased expression of genes related to muscle remodeling (PDGF, COL4A, FBLN, and integrin signaling). NAD+ metabolites were elevated in blood cells of the NMN group. Notably, no significant changes in body composition, blood pressure, or plasma lipids were observed, suggesting the metabolic effects were specifically insulin-sensitizing rather than broadly metabolic.

NR: Trammell et al. (2016) and Martens et al. (2018)

Trammell et al. published the first human pharmacokinetic study of NR in 2016, demonstrating that single oral doses of 100, 300, and 1000 mg of NR (as NIAGEN) produced dose-dependent increases in blood NAD+ levels in healthy volunteers. The 1000 mg dose increased blood NAD+ approximately 2.7-fold above baseline at 8 hours post-dose. The study confirmed that NR was well-tolerated and effectively raised circulating NAD+ metabolites.

Martens et al. (2018) conducted a randomized, placebo-controlled crossover trial in 24 healthy middle-aged and older adults, administering 500 mg NR twice daily for 6 weeks. NR supplementation increased NAD+ levels in peripheral blood mononuclear cells by approximately 60% and showed a trend toward reduced systolic blood pressure (by ~4 mmHg) and reduced aortic stiffness (by ~0.7 m/s pulse wave velocity), though these hemodynamic endpoints did not reach statistical significance in the small sample. The study confirmed the safety and tolerability of chronic NR supplementation.

Stability and Formulation

NMN is relatively stable in dry powder form but degrades in aqueous solution, particularly at elevated temperatures. It is typically supplied as a free base and stored under cool, dry conditions. Some manufacturers have developed enteric-coated or lipid-encapsulated formulations to protect NMN from gastric degradation, though the Slc12a8 transporter identified by Grozio et al. is actually expressed in the small intestine, suggesting gastric protection may be beneficial for directing NMN to its primary absorption site.

NR (marketed as NIAGEN by ChromaDex) is supplied as nicotinamide riboside chloride, a crystalline salt form that provides good shelf stability. NR is susceptible to hydrolysis at high pH and elevated temperatures but is generally stable under standard storage conditions. Its formulation as a chloride salt was developed specifically to address the inherent instability of the free nucleoside form.

Dosing and Research Considerations

In published clinical trials, NMN has been studied at 250 mg/day (Yoshino et al., 2021), while NR has been studied at doses ranging from 100 mg to 2000 mg/day. The Martens et al. trial used 1000 mg/day (500 mg twice daily). Direct dose-equivalence comparisons between NMN and NR are complicated by their different molecular weights (NMN: 334 Da; NR: 255 Da as free base), different absorption mechanisms, and different metabolic fates.

A critical consideration for researchers is tissue specificity. NAMPT expression (the enzyme that converts NAM to NMN in the salvage pathway) varies substantially across tissues, with high expression in liver, adipose tissue, and skeletal muscle. NRK1 and NRK2 expression (the kinases that convert NR to NMN) also varies, with NRK1 broadly expressed and NRK2 enriched in skeletal muscle, heart, and brain. These tissue-specific enzyme expression patterns may influence which precursor is more effective for a given target tissue.

NAD+ Consuming Enzymes: The Demand Side

Understanding NAD+ precursors requires appreciating why NAD+ declines with age in the first place. Three major enzyme families consume NAD+ as a substrate: sirtuins (SIRT1-7), poly(ADP-ribose) polymerases (PARPs, especially PARP1), and CD38/CD157 ectoenzymes.

Camacho-Pereira et al. (2016) demonstrated that CD38 expression increases with age in multiple tissues and that CD38 is a major driver of age-related NAD+ decline. Genetic ablation of CD38 in aged mice prevented NAD+ decline and maintained mitochondrial function. This finding suggests that NAD+ decline is not simply a supply-side problem (insufficient precursor availability) but also a demand-side problem (increased NAD+ consumption by CD38). This has implications for precursor supplementation: if CD38 activity is markedly elevated, simply increasing NAD+ synthesis may be insufficient to restore youthful NAD+ levels, and combining precursors with CD38 inhibitors (such as apigenin or quercetin) may be a more effective strategy.

Summary

NMN and NR represent two complementary strategies for boosting intracellular NAD+ through the salvage pathway. NMN enters cells either directly via the Slc12a8 transporter or after dephosphorylation to NR, and is converted to NAD+ by NMNATs. NR enters cells via equilibrative nucleoside transporters, is phosphorylated to NMN by NRKs, and then follows the same NMNAT-mediated route to NAD+. Clinical data from Yoshino et al. (2021) demonstrated NMN's insulin-sensitizing effects, while Trammell et al. (2016) and Martens et al. (2018) established NR's ability to raise circulating NAD+ levels with good tolerability. Neither precursor has demonstrated superiority in head-to-head clinical trials, and the optimal choice may depend on the target tissue, dosing strategy, and concurrent interventions addressing the demand side of NAD+ metabolism.

*This article is provided for informational and research purposes only. Viking Labs does not sell products intended for human consumption, and nothing in this article should be construed as medical advice.*